Wouldn't the 2014 quarterly revenue numbers and full-year revenue numbers have to be revised upwards now with Monovisc FDA approval ?? Will that be done at the conference call ?? Won't that shoot up the stock price with analysts' upward stock price target revisions ?? I'm excited !!
My dear Mr(?) desair21: I suggest that you use great caution before saying "never" about things from the past that can be accurately ascertained. Anika Therapeutics has been an independent public company for slightly more than 20 years. There is a history. My first 45 shares were acquired by me in 1993 as a spin-off from the parent company, which is now a subsidiary of Bard; I have been following the news about the company ever since then. As one of my favorite ancient sages is reputed to have said, "go and learn."